Welcome to our dedicated page for Virax Biolabs Group news (Ticker: VRAX), a resource for investors and traders seeking the latest updates and insights on Virax Biolabs Group stock.
Virax Biolabs Group Limited (NASDAQ: VRAX) is a biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, with a particular emphasis on T cell-based diagnostics and post-acute infection syndromes (PAIS) such as Long COVID. The VRAX news feed on Stock Titan aggregates company-issued updates and market-moving announcements so readers can follow how Virax’s clinical, regulatory, and financing activities evolve over time.
News about Virax frequently covers progress with its ViraxImmune™ T cell assay and related immune-profiling work. This includes clinical milestones in the United Kingdom, where the company has initiated and completed recruitment for a multi-centre PAIS study conducted with the NHS, and collaborations in the United States, such as its Research Services Agreement with Emory University to generate clinical data in post-viral syndromes including Long COVID. Regulatory interactions, for example Virax’s pre-submission meeting with the U.S. Food and Drug Administration (FDA) and its plans for submissions to the UK Medicines and Healthcare products Regulatory Agency (MHRA), are also key themes in its announcements.
Investors and observers will also find updates on capital markets transactions, such as private placements of ordinary shares and preferred investment options, and corporate governance developments, including board changes and the appointment of directors with diagnostics and MedTech experience. In addition, Virax issues releases on scientific presentations, such as data on T cell dysfunction in PAIS presented at the World Immune Regulation Meeting in Davos.
By following VRAX news, readers can track how Virax advances its immune-profiling platform, responds to Nasdaq listing requirements, and pursues its stated goal of developing T cell-based diagnostics for chronic and post-viral conditions. Bookmark this page to monitor new clinical data, regulatory updates, financing announcements, and scientific disclosures related to Virax Biolabs.
Virax Biolabs Group (Nasdaq: VRAX), a biotechnology company focusing on immune response detection and viral disease diagnostics, announced a $5 million registered direct offering of 1,108,892 ordinary shares at $4.50 per share.
H.C. Wainwright & Co. is the exclusive placement agent. The offering is set to close around August 23, 2024, pending customary conditions.
Gross proceeds are estimated at $5 million, before placement fees and expenses. Net proceeds are intended for working capital and general corporate purposes.
The offering is conducted under a shelf registration statement (Form F-3, Registration No. 333-275893), previously filed with the SEC and declared effective on December 15, 2023. A final prospectus supplement and the base prospectus will be filed and made available on the SEC website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.